Global 2017 Drug Delivery in Central Nervous System

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
81
Global 2017 Drug Delivery in Central Nervous System Diseases Technologies, Markets and Companies Report - Projections to 2026

Dublin, April 17, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies" to their offering. The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance. Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS. Several carrier or transport systems, enzymes, and receptors that control the penetration of molecules have been identified in the BBB endothelium. Receptor-mediated transcytosis can transport peptides and proteins across the BBB. Methods are available to assess the BBB permeability of drugs at the discovery stage to avoid development of drugs that fail to reach their target site of action in the CNS. Many of the new developments in the treatment of neurological disorders will be biological therapies and these will require innovative methods for delivery. Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods. RNA interference (RNAi) as a form of antisense therapy is also described. The role of drug delivery is depicted in the background of various therapies for neurological diseases including drugs in development and the role of special delivery preparations. Pain is included as it is considered to be a neurological disorder. A special chapter is devoted to drug delivery for brain tumors. Cell and gene therapies will play an important role in the treatment of neurological disorders in the future. The method of delivery of a drug to the CNS has an impact on the drug's commercial potential. The market for CNS drug delivery technologies is directly linked to the CNS drug market. Values are calculated for the total CNS market and the share of drug delivery technologies. Starting with the market values for the year 2016, projections are made to the years 2021 and 2026. The markets values are tabulated according to therapeutic areas, technologies and geographical areas. Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS. Finally suggestions are made for strategies to expand CNS delivery markets. Besides development of new products, these include application of innovative methods of delivery to older drugs to improve their action and extend their patent life. Profiles of 76 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and 99 collaborations. These include pharmaceutical companies that develop CNS drugs and biotechnology companies that provide technologies for drug delivery. A number of cell and gene therapy companies with products in development for CNS disorders are included. References contains over 420 publications that are cited in the report. The report is supplemented with 53 tables and 13 figures. Key Topics Covered: Executive Summary 1. Basics of Drug Delivery to the Central Nervous System

2. Blood Brain Barrier

3. Methods of Drug Delivery to the CNS

4. Delivery of Cell, Gene and Antisense Therapies to the CNS

5. Drug Delivery for Treatment of Neurological Disorders

6. Drug delivery for brain tumors

7. Markets for Drug Delivery in CNS Disorders

8. Companies

9. References For more information about this report visit http://www.researchandmarkets.com/research/ql...elivery_in

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Drug Delivery

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 626

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 181

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 60

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 570

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 102

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 92

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 202

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 400

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 189

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 91

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Kal Raman Joins Photon to Drive Strategic AI Innovation Forward

Updated Category News Views 357

Kal Raman Joins Photon as Strategic Advisor to CEO Photon, a leader in digital and AI solutions, is excited to announce that Kal Raman has been appointed as a Strategic Advisor to the CEO. His primary focus will be to work closely with the executive leadership team to build strong relationships with major cloud and technology platforms in the AI ecosystem. This strategic...

Continue Reading
Fiverr's Q3 2024: Growth Strategies and Financial Insights

Updated Category News Views 319

Fiverr Reports Strong Q3 2024 Results Fiverr International Ltd. (NYSE: FVRR) has delivered impressive financial results for the third quarter of 2024. This success demonstrates the company's commitment to enhancing its services and reaching growth targets even amidst a challenging economic environment. Fiverr's strategy focuses on increasing its take rate by offering...

Continue Reading
Upcoming Legal Action for Jasper Therapeutics Investors Explained

Updated Category News Views 234

Legal Investigation Updates for Jasper Investors As the legal landscape around Jasper Therapeutics, Inc. (NASDAQ: JSPR) evolves, important updates are emerging for investors affected by recent developments. Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating claims on behalf of shareholders who may have suffered losses due to the...

Continue Reading
Naf Naf Grill Unveils Flavor-Packed Spiced Meatballs Today

Updated Category News Views 91

Introducing Spiced Meatballs at Naf Naf Grill Naf Naf Grill has just launched an exciting new dish: Spiced Meatballs. These flavorful meatballs are crafted with care to showcase the vibrant essence of Middle Eastern cuisine, making them a perfect addition to enhance your dining experience this fall. Rich Middle Eastern Flavors Made from 100% beef, these Spiced Meatballs...

Continue Reading
Pulmatrix Shares Q1 2025 Financial Results and New Directions

Updated Category News Views 170

Overview of Pulmatrix's Recent Developments Pulmatrix, Inc. is a biopharmaceutical entity focused on developing innovative inhaled therapeutic products to treat migraine and respiratory diseases, utilizing its specialized iSPERSE™ technology. In a recent announcement, the company outlined its financial performance for the first quarter of 2025. Key Financial Outcomes...

Continue Reading